• Lepu Scientech agreed to buy a 54.24% stake in Shanghai Minwei Biotech from Lepu Medical for RMB 1.09 billion cash.
• Payment set at RMB 653.03 million on closing conditions, followed by RMB 435.36 million within 18 months of registration changes.
• Deal would make Minwei a non-wholly owned subsidiary, adding drug R&D in cardiovascular and metabolic diseases to Lepu Scientech’s portfolio.
• Minwei recorded 2025 revenue of RMB 226.9 million, net profit of RMB 28.98 million, total assets of RMB 491.97 million.
• Minwei out-licensed MWN105 to Denmark’s Sidera in 2025, with potential milestone payments up to US$ 1.01 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Scientech Medical Technology Shanghai Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294842), on August 21, 2026, and is solely responsible for the information contained therein.